303 related articles for article (PubMed ID: 23399641)
21. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
22. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
23. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
24. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
Race PR; Lovering AL; White SA; Grove JI; Searle PF; Wrighton CW; Hyde EI
J Mol Biol; 2007 Apr; 368(2):481-92. PubMed ID: 17350040
[TBL] [Abstract][Full Text] [Related]
25. Engineering
Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
[TBL] [Abstract][Full Text] [Related]
26. Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.
Swe PM; Copp JN; Green LK; Guise CP; Mowday AM; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2012 Sep; 84(6):775-83. PubMed ID: 22796568
[TBL] [Abstract][Full Text] [Related]
27. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
28. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW
J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
30. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
31. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
32. An unusually cold active nitroreductase for prodrug activations.
Çelik A; Yetiş G
Bioorg Med Chem; 2012 Jun; 20(11):3540-50. PubMed ID: 22546205
[TBL] [Abstract][Full Text] [Related]
33. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.
Lipinski KS; Djeha AH; Ismail T; Mountain A; Young LS; Wrighton CJ
Mol Ther; 2001 Oct; 4(4):365-71. PubMed ID: 11592840
[TBL] [Abstract][Full Text] [Related]
34. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
35. Nitroreductase activation of CB1954--an alternative 'suicide' gene system.
Bailey SM; Hart IR
Gene Ther; 1997 Feb; 4(2):80-1. PubMed ID: 9081709
[No Abstract] [Full Text] [Related]
36. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
37. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF
Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200
[TBL] [Abstract][Full Text] [Related]
38. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
39. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
